Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD

NCT01862926 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

104

Enrollment

OTHER

Sponsor class

Conditions

Interstitial Lung Disease
Scleroderma
Idiopathic Inflammatory Myositis
Mixed Connective Tissue Disease

Interventions

DRUG: Rituximab
DRUG: Cyclophosphamide

Sponsor

Royal Brompton & Harefield NHS Foundation Trust

Collaborators

[object Object]
[object Object]
[object Object]